Spironolactone use and renal toxicity: population based longitudinal analysis. by Wei, L et al.
RESEARCH
Spironolactone use and renal toxicity: population based
longitudinal analysis
Li Wei, lecturer,1 Allan D Struthers, professor,2 Tom Fahey, professor,3 Alexander D Watson, general
practitioner,4 Thomas M MacDonald, professor1
ABSTRACT
Objective To determine the safety of spironolactone
prescribing in the setting of the UK National Health
Service.
Design Population based longitudinal analysis using a
record linkage database.
Setting Tayside, Scotland.
Population All patients who received one or more
dispensed prescriptions for spironolactone between
1994 and 2007.
Main outcome measures Rates of prescribing for
spironolactone, hospital admissions for hyperkalaemia,
andhyperkalaemia and renal functionwithout admission,
before and after the publication of results from the
Randomised Aldactone Evaluation Study (RALES).
Results Prescriptions for spironolactone and
measurements of serum creatinine and serum potassium
all increased in parallel in Tayside after the release of the
RALES results in 1999 (from 2847, 5345, and 5246 in the
first half of 1999 to 6582, 10753, and 10534 by the
second half of 2001, and to 8619, 17844, and 17649 by
2007). These increases occurred in patients with and
without heart failure. Few hospital admissions for
hyperkalaemia occurred over this time: three in the first
quarter of 1995, two in the last quarter of 2001, and three
in 2007. Among patients who were taking angiotensin
converting enzyme inhibitors and who had recently been
admitted to hospital for heart failure, the rate of
spironolactone use was 19.8 per 100 patients in early
1999 rising to 70.1 per 100 patients by late 2001 (P<0.01)
and 61.3 by 2007. The rate of outpatient measured
hyperkalaemia (serum K+>6 mmol/l) did not increase over
time (9.9 per 100 patients in early 1999, 6.9 per 100
patients in late 2001, and 2.9 per 100 patients in 2007)
despite the increased use of spironolactone.
Conclusions Despite a marked increased in the use of
spironolactone in patients with and without heart failure,
no increase was seen in hospital admissions for
hyperkalaemia and outpatient hyperkalaemia actually
fell. Careful monitoring of patients prescribed
spironolactone seems to have been associated with no
increase in risk of hyperkalaemia.
INTRODUCTION
The mineralocorticoid antagonist spironolactone is
efficacious in patients with heart failure.1 It is also effec-
tive in patients with resistant hypertension, primary
aldosteronism, and cirrhosis with secondary
aldosteronism.2-4 A recent study showed that a rapid
increase in use of spironolactone occurred in Canadian
patients with heart failure concurrently treated with an
angiotensin converting enzyme (ACE) inhibitor after
the publication of the Randomised Aldactone Evalua-
tion Study (RALES).15 However, a marked concurrent
increase in hospital admissions with (and subsequent
deaths from) hyperkalaemia also occurred. We
believed that the risk associated with use of spironolac-
tonewasmanagedbetter inour region (Tayside) than in
Canada and that serious adverse effects were very rare.
To test whether we had similar adverse effects to those
seen in Canada, we did a population based study link-
ing the dispensed prescribing of spironolactone with
hospital admissions forhyperkalaemia and renal failure
and results of biochemical monitoring in outpatients.
METHODS
We did this study in the population of Tayside in Scot-
land, using the MEMO (Medicines Monitoring Unit)
record linkage database.6 TheMEMOdatabase covers
a geographically compact population and serves about
400 000 patients in theNationalHealth Service in Scot-
land, 97% of whom are white. In brief, this database
contains several datasets including all dispensed com-
munity prescriptions, hospital discharge data, and
other data that are linked by a unique patient identifier,
the community health index number. The data have
been validated and made anonymous for the purposes
of research, as approved by the government appointed
guardians of patient confidentiality.
Study design and population
This was a population based longitudinal analysis using
the MEMO record linkage database in people resident
in Tayside and registered with a general practitioner
between January 1994andDecember 2007.We studied
patients who were treated with spironolactone between
January 1994 and December 2001. We compared the
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data on spironolactone prescriptions and serum creati-
nine/potassiummeasurements before and after the date
of online release of the RALES results. This period of
time matched that of the Canadian study,3 which
enabled us to compare the two studies.We did a further
analysis between 2005 and 2007 to determine whether
these trends persisted. For technical reasons, the data
were incomplete between 2002 and 2004.
Definitions
Wedefined patientswith heart failure as thosewhohad
a hospital admission for heart failure with an ICD-9
(international classification of diseases, 9th revision)
diagnostic code of 428 or an ICD-10 code of I50. We
defined patients with liver cirrhosis as those who had a
hospital admission for liver failure with an ICD-9 code
of 571 or an ICD-10 code of K70 or K74. Patients with
hypertension were those who were on spironolactone
treatment and who did not have a diagnosis of heart
failure or liver cirrhosis (presumed to bemostly hyper-
tensive patients).
Biochemical datawere available for the entire region
(primary and secondary care) from 1995 onwards.We
defined spironolactone associated hyperkalaemia as
serum potassium greater than 6 mmol/l in a patient
taking spironolactone treatment.
Outcome variables
The outcomemeasureswere rates of prescribing for spir-
onolactone, any hospital admission for hyperkalaemia,
any outpatient serum potassium above 6 mmol/l, and
serum creatinine above 220 μmol/l.
Statistical analysis
Weused a sixmonth interval in the time series data for
spironolactone prescriptions and serum measure-
ments of creatinine and potassium. We used a regres-
sion model that takes into account autocorrelation
between themeasures over time to assesswhether asso-
ciations existed between spironolactone prescribing
and biochemistry measurements. We examined rates
of spironolactone prescriptions, hospital admissions
for hyperkalaemia, and serummeasurements for crea-
tinine and potassium before and after the release of the
RALES study results. We did a trend test to check
whether spironolactone prescriptions and measure-
ments of serum creatinine/potassium increased over
the entire study period. We compared hyperkalaemia
associated with spironolactone prescribing between
patients with heart failure, liver cirrhosis, and hyper-
tension.We summarised data as mean (SD) or median
(interquartile range) for continuous variables andnum-
ber (percentage) of patients for categorical variables.
We did χ2 tests and Kruskal-Wallis tests to determine
significant differences in patients’ characteristics
between the three groups.We used SAS software (ver-
sion 9.1) for all statistical analyses.
RESULTS
Spironolactone use in Tayside population
The number of spironolactone prescriptions and the
number of patients who were taking spironolactone
rose significantly after the release of the RALES
study results (September 1999) from 1018 patients
with 2847 prescriptions in the first half of 1999 to
2067 patients with 6582 prescriptions by the second
half of 2001. We also saw an increase in recent years,
with 2564 patients and 8619 prescriptions in the first
half of 2007 (fig 1). Tayside has a very stable popula-
tion, so prescription numbers reflect the rate of pre-
scribing. The proportions of patients who were taking
low dose (≤25mg/day), medium dose (26-50mg/day),
and high dose (>50 mg/day) spironolactone were
50.8%, 24.9%, and 24.3% for patients with heart failure
(n=1235); 6.5%, 15.9%, and 77.6% for patients with
liver cirrhosis (n=340); and 33.9%, 32.8%, and 33.3%
for patientswith hypertension (n=5883) during the per-
iod 1994-2001.
Serum measurements and hospital admissions
Measurements of serum creatinine and serum potas-
sium increased in parallel in patients who were taking
spironolactone in Tayside after the release of the
RALES results in 1999 (from 5345 and 5246 in the
first half of 1999 to 10 753 and 10 534 by the second
half of 2001). These increases before and after July
1999 were statistically significant (P<0.01). These
increases occurred in patients with and without heart
failure and continued in recent years (to 17 844 and
17 649 in 2007). The regression coefficient was 2.18
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Fig 1 | Spironolactone prescriptions (top) and prescribing
rates (bottom) for different indications in Tayside population
between 1994 and 2007. HF=heart failure; LC=liver cirrhosis
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(SE=0.18, P<0.01) between spironolactone use and
serum creatinine or potassium measurements. The
numbers/rates of high serum creatininemeasurements
(>220 μmol/l) and of hyperkalaemia (serumpotassium
measurements >6 mmol/l) did not increase signifi-
cantly after the publication ofRALES (fig 2).However,
the rate of mild hyperkalaemia (defined as serum
potassium >5 mmol/l but ≤6 mmol/l) increased over
the study period (see web extra figure), suggesting that
mild hyperkalaemia was appropriately identified and
managed to avoid development of clinically significant
hyperkalaemia. Few hospital admissions for hyperka-
laemia occurred over time, ranging from three in the
first quarter of 1995 to two in the last quarter of 2001
and three in 2007; we found no significant trend for
increased hyperkalaemia (trend test, P=0.12) over the
entire study period. We found a significant trend for
serum creatinine measurements >220 µmol/l
(P<0.01) over the study period, but this trend did not
mirror increased spironolactone use.
Spironolactone use among patients with heart failure
receiving ACE inhibitors
Figure 3 shows spironolactone use and hyperkalaemia
(defined as serum potassium >6 mmol/l) in patients
recently admitted to hospital for heart failure who
were receiving angiotensin converting enzyme (ACE)
inhibitors. Use of spironolactone increased after the
online release of the RALES results, from 19.8 per
100 patients in the first half of 1999 to 70.1 per 100
patients by the second half of 2001 (P<0.01) and 61.3
in 2007. However, the rates of hyperkalaemia did not
increase over time (from 9.9 per 100 patients in early
1999 to 6.9 per 100 patients by late 2001 (P<0.01) and
2.9 in 2007). We found no impact of the RALES study
on use of aspirin and statins over time (fig 3). However,
statin use rose gradually over time (trend test, P<0.01),
reflecting the impact of statins in the primary and sec-
ondary prevention of coronary heart disease. 7-11
Characteristics of patients with spironolactone associated
hyperkalaemia
Between 1995 and 2001, 578 patients had spironolac-
tone associated hyperkalaemia (defined as serum
potassium >6 mmol/l). The table shows the character-
istics of these patients with heart failure, liver cirrhosis,
and hypertension. We found no significant differences
in sex or rates of hyperkalaemia between the three
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Fig 2 | Serum measurements of creatinine/potassium (top)
and rates of measurements (bottom) in Tayside population
between 1995 and 2007
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Fig 3 | Rates of spironolactone prescriptions and
hyperkalaemia among patients recently admitted to hospital
for heart failure who were receiving angiotensin converting
enzyme inhibitors, and rates of aspirin and statins prescribing
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groups of patients. Patients in the liver cirrhosis group
were younger and more socially deprived and had
used higher doses of spironolactone compared with
patients in the heart failure and hypertension groups.
The proportions with high creatinine (>220 μmol/l) at
any time before the date of hyperkalaemia during the
same period were 76% (n=130) in the heart failure
group, 71% (n=32) in the liver cirrhosis group, and
53% (n=192) in the hypertension group (P<0.01), indi-
cating that renal impairment is a potential risk factor
and presages hyperkalaemia associated with spirono-
lactone use.Of these 578 patients, 451 (78.0%) stopped
taking spironolactone and 33 (5.7%) reduced the dose
during the follow-up period.
DISCUSSION
We saw an increased use of spironolactone in patients
with heart failure after the report of the RALES study
results in late 1998. This trend continued after the
online release of RALES, which is consistent with the
findings from a Canadian study that showed an
increase in the spironolactone prescription rate from
34 per 1000 patients in 1994 to 149 per 1000 patients
by late 2001.5 The use of spironolactone alsomarkedly
increased in patients with hypertension, but this
increase pre-dated the RALES results reflecting a
local research interest in spironolactone use in hyper-
tension and the British Hypertension Society
guidelines.2 12-15 Concurrent with this increased use of
spironolactone, measurement of serum potassium and
creatinine also increased, suggesting that patients who
were at risk from spironolactone use were monitored
(andpresumablymanaged)well. In support of this con-
cept, we found an increase in mild hyperkalaemia but
no increase in more severe hyperkalaemia. Perhaps as
a result of this, serious renal side effects were rare.
Our data support the view that propermonitoring in
the community improves care and delivers maximum
benefit to patients.16 Unlike the Canadian study,5
which reported a considerable increase in the rate of
hospital admission for hyperkalaemia, we did not see
such an increase; nor did we see an increase in severe
biochemical hyperkalaemia over time.Our results sug-
gest that the benefit of spironolactone in patients with
heart failure and hypertension can be realised in a “real
world” population if this drug is carefully monitored.
This highlights the usefulness of monitoring as a risk
management tool and shows that proper monitoring
can deliver substantial benefits for patients. This is an
important observation, as a recent study showed that
between 2005 and 2007 less than a third of eligible
patients admitted to hospital for heart failure and par-
ticipating in a quality improvement registry received
aldosterone antagonist treatment as recommended by
heart failure guidelines.17
The RALES study results had amajor impact on use
of spironolactone in patients with heart failure.18 19 In
parallel, the 2004 British Hypertension Society guide-
lines recommended that spironolactone should be
used as fourth line treatment and also resulted in a
marked increase in the use of this drug, often added
for patients already taking polytherapy.20 More
recently, studies have shown the benefit of spironolac-
tone in patients with and without hyperaldosteronism
and patients with resistant hypertension.4 21 Increased
aldosterone concentrations within the physiological
range predisposed to the development of
hypertension.22 Renewed interest inmineralocorticoid
antagonism thus exists.
Among patients who had spironolactone associated
hyperkalaemia, 75% were over 65 years old, 61% had
high serumcreatininebefore thedevelopment of hyper-
kalaemia, and 44%were taking a high daily dose of spir-
onolactone. This highlights the need to monitor this
group of patients even more carefully, as previous stu-
dies have shown that older patients are at higher risk of
spironolactone associated hyperkalaemia.23-25
Our study has limitations. Firstly, the results reflect
only one NHS region. However, we would expect
other regions of the NHS to have similar monitoring
systems. Secondly, we used ICD-9 and ICD-10 codes
for hospital admission due to heart failure and liver
disease, which may be subject to some degree of mis-
classification because of changes in coding patterns.
Thirdly, this is an observational study. We did not
adjust for any other risk factors, and we cannot rule
out residual confounding. Further study on this topic
in a large population would strengthen the evidence of
safe spironolactone use in patients with heart failure.
Conclusion
The risk associated with use of spironolactone can be
managed in the setting of the NHS, and adverse effects
can be minimised. Our data provide reassurance that
spironolactone is a safe drug in heart failure, hyperten-
sion, and liver disease when it is used in conjunction
with appropriate monitoring.
Characteristics of patients who developed spironolactone associated hyperkalaemia (serum
K+>6 mmol/l) between 1995 and 2001. Values are numbers (percentages) unless stated
otherwise
Characteristics
Heart failure
(n=172)
Liver cirrhosis
(n=45)
Hypertension
(n=361) P value
Median (interquartile range) serum K+
concentration (mmol/l)
6.4 (6.2-6.7) 6.4 (6.2-6.7) 6.4 (6.2-6.8) 0.889
Sex:
Men 91 (53) 20 (44) 156 (43)
0.107
Women 81 (47) 25 (56) 205 (57)
Mean (SD) age 73.2 (9.7) 55.6 (12.5) 72.8 (12) <0.001
Social deprivation:
1 11 (6) 3 (7) 16 (4)
<0.001
2 37 (22) 8 (18) 75 (21)
3 37 (22) 7 (16) 108 (30)
4 27 (16) 9 (20) 78 (22)
5 19 (11) 3 (7) 35 (10)
6 and 7 41 (24) 15 (33) 48 (13)
Spironolactone daily dose:
≤25 mg 61 (36) 0 90 (25)
<0.00126-50 mg 49 (29) 5 (11) 117 (32)
>50 mg 62 (36) 40 (89) 154 (43)
Creatinine concentration >220 μmol/l 130 (76) 32 (71) 192 (53) <0.001
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Spironolactone is efficacious in patients with heart failure, resistant hypertension, and liver
cirrhosis with secondary aldosteronism
A Canadian study found an alarming rate of hyperkalaemia due to spironolactone use in
patients with heart failure
Monitoring patients at risk of adverse drug reactions can improve the benefit/risk ratio
WHAT THIS STUDY ADDS
No increased hyperkalaemia or renal toxicity occurred in association with increased use of
spironolactone in patients with heart failure, hypertension, or liver disease
Spironolactone prescribing seems to be safe in the setting of the NHS, probably owing to
careful monitoring of electrolytes and renal function
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